|
|
|
|
|
08.05.25 - 13:03
|
ProQR Announces First Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update....
|
|
|
02.05.25 - 14:03
|
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT....
|
|
|
14.04.25 - 13:03
|
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage....
|
|
|
|
|
13.03.25 - 12:03
|
ProQR Announces Year End 2024 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2024, and provided a business update....
|
|
|
12.12.24 - 13:12
|
ProQR expands partnership with RSRT to advance Rett Syndrome therapy (PBR)
|
|
|
The total funding is set to amount to $9.1m and the initial research grant of $1m was announced in January this year. The additional funding from RSRT will
The post ProQR expands partnership with RSRT to advance Rett Syndrome therapy appeared first on Pharmaceutical Business review....
|
|
|
10.12.24 - 14:06
|
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform....
|
|
|
25.10.24 - 22:48
|
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire EN)
|
|
|
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR....
|
|
|
|
|
|
|
23.10.24 - 04:18
|
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,700,000 additional ordinary shares at the public offering price, less underwriting discounts and commissions....
|
|
|
22.10.24 - 22:03
|
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual terms of the Offering....
|
|
|
18.10.24 - 09:30
|
Durchbruch bei RNA-Editierung zündet mehrere Börsenraketen (Sharedeals)
|
|
|
Die Aktie des niederländischen Biotech-Unternehmens ProQR Therapeutics (WKN: A12B97) ist am Mittwoch um +122% in die Höhe geschnellt. Grund dafür waren positive Studienergebnisse eines Konkurrenten, die den gesamten Sektor der RNA-Editierung beflügelten. NBC-Mitglieder verbinden beste Erinnerungen mit dem Unternehmen, Analysten sehen weiteres Kurspotenzial. Durchbruch bei klinischer Studie sorgt für Börsen-Euphorie Wave Life Sciences – ein […]
The post Durchbruch bei RNA-Editierung zündet mehrere Börsenraketen first appeared on sharedeals.de....
|
|
|
07.10.24 - 14:03
|
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, October 6-9, 2024, in Montreal, QC, Canada....
|
|
|
|
|
10.09.24 - 22:33
|
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the 2024 Cantor Global Healthcare Conference in New York City on Tuesday, September 17 at 9:10 am ET....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
